Pharma Vision SRL
The score of Pharma Vision shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +23 % Total assets -28 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Pharma Vision's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 61,409 € | ||||
| Equity | 117,198 € | ||||
| Cash | 103,044 € | ||||
| EBITDA | 113,080 € | ||||
| Total assets | 288,758 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 02 Oct 2026
- Year ended 31 Dec 2024filed on 16 Sep 2025
- Year ended 31 Dec 2023filed on 03 Jul 2024
- Year ended 31 Dec 2022filed on 28 Aug 2023
- Year ended 31 Dec 2021filed on 28 Jul 2022
Pharma Vision's financial analysis
- Solvency40.6%sector median: 50.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Pharma Vision
Pharma Vision's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0875.626.918
- VAT number
- BE0875626918
- Peppol
- Registered · 0208:0875626918 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 19 Aug 2005
- Registered office
- 1082 Berchem-Sainte-Agathe
- Latest accounts
- 2025 · filed on 02 Oct 2026
- Activity
- Business and other management consultancy activities (NACE 70200)
Pharma Vision (SRL) has been based in Berchem-Sainte-Agathe since 2005, active in: business and other management consultancy activities. For 2025, it reports a net profit of 61,409 € and equity of 117,198 €; its revenue is not published. Its solvency stands at 40.6%, below the median of its sector (50.7%).
Companies similar to Pharma Vision
Companies in the same business, of comparable size and area, outside its group.
- Contrabas Business and other management consultancy activities Knokke-Heist · balance sheet 288,763 €
- Ducofin Business and other management consultancy activities Menen · balance sheet 288,811 €
- De Geeter & Co Business and other management consultancy activities Boom · balance sheet 288,673 €
- PEAC Business and other management consultancy activities Aalst · balance sheet 288,874 €
- KDK Consult Business and other management consultancy activities Halle · balance sheet 288,915 €
- Instigo Business and other management consultancy activities Rotselaar · balance sheet 288,967 €
- SR2L Business and other management consultancy activities Wezembeek-Oppem · balance sheet 288,478 €
- Federation Wallonne DE Services DU Brabant-Wallon Business and other management consultancy activities Perwez · balance sheet 288,443 €
Frequently asked questions about Pharma Vision
What is the revenue of Pharma Vision?
Pharma Vision files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Pharma Vision?
In Belgium, the VAT number is the company number prefixed with BE: BE0875626918 for Pharma Vision, if the company is VAT-registered. Its company number (CBE) is 0875.626.918.
Where is the registered office of Pharma Vision?
According to the CBE register, the registered office of Pharma Vision is in 1082 Berchem-Sainte-Agathe.
What is the equity of Pharma Vision?
At the close of the 2025 financial year, the equity of Pharma Vision amounts to 117,198 €, a solvency of 40.6% of total assets.
Who manages Pharma Vision?
The register lists 1 active mandates at Pharma Vision. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Pharma Vision
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →